{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:29:05Z","timestamp":1775251745537,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pancreas"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A workshop was sponsored by the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, on July 25, 2018, in Pittsburgh, Penn. The workshop was designed to bring together a multidisciplinary group of experts to accelerate the development of therapeutics for clinical application in inflammatory diseases of the exocrine pancreas. Three separate working groups (acute pancreatitis, recurrent acute pancreatitis, and chronic pancreatitis) were formed to address the needs, gaps, and opportunities. The working groups included patients with pancreatic diseases, pharmaceutical company leaders, basic scientists, clinical researchers, and representatives from the US Food and Drug Administration to assist with regulatory considerations and to identify the unmet needs, research targets, and opportunities to provide direction for successful development of therapeutic agents in these diseases. This article represents the summary of the overview presentations at the National Institute of Diabetes and Digestive and Kidney Diseases workshop including an ongoing drug trial in acute pancreatitis; a successful drug development network developed by the Cystic Fibrosis Foundation; and considerations for subject selection in drug trials, incorporating Food and Drug Administration guidelines on clinical trial design and clinical outcome measures. The summaries of each working group follow separately in accompanying articles.<\/jats:p>","DOI":"10.1097\/mpa.0000000000001176","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T15:14:33Z","timestamp":1539702873000},"page":"1180-1184","source":"Crossref","is-referenced-by-count":12,"title":["Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis\u2014Knowledge Gaps and Research Opportunities"],"prefix":"10.1097","volume":"47","author":[{"given":"Aliye","family":"Uc","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology, Pancreatology, and Nutrition, Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana K.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drucy","family":"Borowitz","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Foundation, Bethesda, MD;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marshall J.","family":"Glesby","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Weill Cornell School of Medicine, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Mayerle","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Ludwig Maxmilian University and Polyklinik, Munich, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Sutton","sequence":"additional","affiliation":[{"name":"Royal Liverpool University Hospital and Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Pandol","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230822","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.gastro.2012.11.018","article-title":"Advances in acute and chronic pancreatitis: from development to inflammation and repair","volume":"144","year":"2013","journal-title":"Gastroenterology"},{"key":"bib2-20230822","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/MPA.0000000000000713","article-title":"Chronic pancreatitis in the 21st century\u2014research challenges and opportunities: summary of a National Institute of Diabetes and Digestive and Kidney Diseases workshop","volume":"45","year":"2016","journal-title":"Pancreas"},{"key":"bib3-20230822","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/MPA.0b013e3182a9ad9d","article-title":"Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop","volume":"42","year":"2013","journal-title":"Pancreas"},{"key":"bib4-20230822","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/MPA.0000000000001037","article-title":"The interface of pancreatic cancer with diabetes, obesity, and inflammation: research gaps and opportunities: summary of a National Institute of Diabetes and Digestive and Kidney Diseases workshop","volume":"47","year":"2018","journal-title":"Pancreas"},{"key":"bib5-20230822","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1053\/j.gastro.2012.03.005","article-title":"Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis","volume":"142","year":"2012","journal-title":"Gastroenterology"},{"key":"bib6-20230822","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrgastro.2014.39","article-title":"Treatment options for acute pancreatitis","volume":"11","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"bib7-20230822","first-page":"CD011384","article-title":"Pharmacological interventions for acute pancreatitis","volume":"4","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"bib8-20230822","first-page":"481.e7","article-title":"Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"bib9-20230822","first-page":"CD002941","article-title":"Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis","volume":"5","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"bib10-20230822","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/shk.0b013e3180487ba1","article-title":"Role of tumor necrosis factor-alpha in acute pancreatitis: from biological basis to clinical evidence","volume":"28","year":"2007","journal-title":"Shock"},{"key":"bib11-20230822","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1177\/1060028014540869","article-title":"Effect of tumor necrosis factor-\u03b1 inhibitors on drug-induced pancreatitis in inflammatory bowel disease","volume":"48","year":"2014","journal-title":"Ann Pharmacother"},{"key":"bib13-20230822","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1378\/chest.12-1639","article-title":"Cystic fibrosis therapeutics: the road ahead","volume":"143","year":"2013","journal-title":"Chest"},{"key":"bib14-20230822","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/thoraxjnl-2012-202550","article-title":"Progress in cystic fibrosis and the CF Therapeutics Development Network","volume":"67","year":"2012","journal-title":"Thorax"},{"key":"bib15-20230822","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-3476(94)70301-9","article-title":"Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference","volume":"124","year":"1994","journal-title":"J Pediatr"},{"key":"bib16-20230822","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/35015728","article-title":"Pharmacogenetics and the practice of medicine","volume":"405","year":"2000","journal-title":"Nature"},{"key":"bib17-20230822","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fpubh.2018.00032","article-title":"Variation in research designs used to test the effectiveness of dissemination and implementation strategies: a review","volume":"6","year":"2018","journal-title":"Front Public Health"},{"key":"bib19-20230822","doi-asserted-by":"crossref","first-page":"e018320","DOI":"10.1136\/bmjopen-2017-018320","article-title":"Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov","volume":"8","year":"2018","journal-title":"BMJ Open"},{"key":"bib20-20230822","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMe0810630","article-title":"Pharmacogenetics\u2014tailoring treatment for the outliers","volume":"360","year":"2009","journal-title":"N Engl J Med"},{"key":"bib21-20230822","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/CLEP.S156708","article-title":"Critical concepts in adaptive clinical trials","volume":"10","year":"2018","journal-title":"Clin Epidemiol"},{"key":"bib22-20230822","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib23-20230822","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hep4.1079","article-title":"Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic","volume":"1","year":"2017","journal-title":"Hepatol Commun"},{"key":"bib24-20230822","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1513\/pats.200703-039BR","article-title":"Patient-reported outcomes in cystic fibrosis","volume":"4","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"bib25-20230822","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41395-018-0087-7","article-title":"Recurrent acute pancreatitis significantly reduces quality of life even in the absence of overt chronic pancreatitis","volume":"113","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"bib26-20230822","year":"2009","journal-title":"Patient-reported Outcome Measures: use in Medical Product Development to Support Labeling Claims"},{"key":"bib27-20230822","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","year":"2015","journal-title":"JAMA Oncol"},{"key":"bib28-20230822","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/ajg.2016.225","article-title":"Pancreatitis Quality of Life Instrument: a psychometric evaluation","volume":"111","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"bib29-20230822","doi-asserted-by":"crossref","first-page":"2050312114520856","DOI":"10.1177\/2050312114520856","article-title":"Pancreatitis Quality of Life Instrument: development of a new instrument","volume":"2","year":"2014","journal-title":"SAGE Open Med"},{"key":"bib30-20230822","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pain.2005.08.025","article-title":"The Bath Adolescent Pain Questionnaire (BAPQ): development and preliminary psychometric evaluation of an instrument to assess the impact of chronic pain on adolescents","volume":"118","year":"2005","journal-title":"Pain"},{"key":"bib31-20230822","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jpain.2010.02.005","article-title":"PROMIS Pediatric Pain Interference Scale: an item response theory analysis of the pediatric pain item bank","volume":"11","year":"2010","journal-title":"J Pain"},{"key":"bib32-20230822","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.pain.2008.06.022","article-title":"Validation of a self-report questionnaire version of the Child Activity Limitations Interview (CALI): the CALI-21","volume":"139","year":"2008","journal-title":"Pain"},{"key":"bib33-20230822","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pain.2004.02.023","article-title":"Development and validation of the Child Activity Limitations Interview: a measure of pain-related functional impairment in school-age children and adolescents","volume":"109","year":"2004","journal-title":"Pain"},{"key":"bib34-20230822","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.ajp.0000205257.80044.01","article-title":"Mothers' responses to children's pain","volume":"22","year":"2006","journal-title":"Clin J Pain"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006676-201811000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:19:00Z","timestamp":1775247540000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-201811000-00004"}},"subtitle":["Overview Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop"],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000001176","relation":{},"ISSN":["1536-4828","0885-3177"],"issn-type":[{"value":"1536-4828","type":"electronic"},{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}